Cardiac arrest is a leading cause of death in the United States and currently, therapeutic hypothermia, now called targeted temperature management (TTM), is the only recent treatment modality proven to increase survival rates and reduce morbidity for this condition. Shivering and subsequent metabolic stress, however, limits application and benefit of TTM. Stimulating CNS A1 adenosine receptors inhibits shivering and non-shivering thermogenesis in rats and induces a hibernation-like response in hibernating species. Here we investigated the pharmacodynamics of two A1AR agonists in development as anti-shivering agents. To optimize body temperature (Tb) control we evaluated the influence of every-other-day feeding, 
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Abstract:
Cardiac arrest is a leading cause of death in the United States and currently, therapeutic hypothermia, now called targeted temperature management (TTM) , is the only recent treatment modality proven to increase survival rates and reduce morbidity for this condition. Shivering and subsequent metabolic stress, however, limits application and benefit of TTM. Stimulating CNS A1 adenosine receptors inhibits shivering and non-shivering thermogenesis in rats and induces a hibernation-like response in hibernating species. Here we investigated the pharmacodynamics of two A1AR agonists in development as anti-shivering agents. To optimize body temperature (Tb) control we evaluated the influence of every-other-day feeding, dose, drug and ambient temperature (Ta) on the Tb lowering effects of N 6 -cyclohexyladenosine (CHA) and the partial A1AR agonist capadenoson in rats. The highest dose of CHA (1.0 mg/kg, IP) caused all ad libitum fed animals tested to reach our target Tb of 32°C, but responses varied and some rats over-cooled to a Tb as low as 21°C at 17.0°C Ta. Dietary restriction normalized the response to CHA. The partial agonist capadenoson (1.0 or 2.0 mg/kg, IP) produced a more consistent response but the highest dose decreased Tb by only 1.6°C. To prevent overcooling after CHA we studied continuous IV administration in combination with dynamic surface temperature control. Results show that after CHA administration control of surface temperature maintains desired target Tb better than dose or ambient temperature.
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Introduction
Hypothermia is defined as a body temperature colder than 35°C and is a well-known cause of death in cold climates. Despite this, the American Heart Association (Callaway et al., 2015a) guidelines for CPR & Emergency Cardiovascular Care strongly recommend induced hypothermia via targeted temperature management (TTM) for treating out-of-hospital cardiac arrest (OHCA), and neonatal resuscitation. Clinical trials for TTM in stroke, the leading cause of adult disability (Mozaffarian et al., 2015) are ongoing (Lyden et al., 2016) . While cooling is neuroprotective, clinical application is complicated by side-effects such as shivering.
Paralytics suppress shivering and are used commonly with TTM in comatose patients after cardiac arrest (Bernard et al., 2002) . With regard to cooling conscious stroke patients, meperidine (IV) in combination with buspirone (oral) is currently the treatment of choice to suppress shivering. Synergy between these two drugs decreases shivering threshold to a core body temperature (T b) of 33.5°C with minimal risk of respiratory depression,(Logan et al., 2011) (Mokhtarani et al., 2001; Sessler, 2009) however, a shivering threshold of 33.5°C is not sufficient for optimal control of shivering at colder Tb. The metabolic stress of shivering limits maximum therapeutic benefit of cooling. A recent study (Nielsen et al., 2013) showed no JPET #241315 (IP) using N 6 cyclohexyladenosine (CHA) decreases oxygen consumption (V O2) and leads to a subsequent decrease in Tb in a manner that resembles spontaneous onset of hibernation (Jinka et al., 2011) . However, for unknown reasons, the drug is effective only in the hibernation season. Like the hibernation season in AGS, dietary restriction (DR) in rats sensitizes animals to the temperature lowering effects of CHA when compared to their ad libitum (AL) fed counterparts (Jinka et al., 2010) . Although CHA effectively lowers Tb in DR rats, precise control of target temperature has not been achieved in AL rats; and DR is not a viable option for human emergency medicine. Currently, it is not known how dose and environmental temperature influences final body temperature in AL rats when given CHA, an A1 selective full agonist (van der Wenden et al., 1995) or capadenoson, an A1 selective partial agonist (Albrecht-Kupper et al., 2012) . The objective of this study was to characterize how dose of CHA, the partial A1AR agonist capadenoson, and environmental temperature influence Tb in freely fed rats for the purpose of precise control of Tb between 32-36°C. We measure the rate of oxygen consumption as an indicator of thermogenesis, define individual variability in response to capadenoson and to CHA at a dose higher than tested previously and show that ambient temperature alone is not sufficient to control the depth of cooling. We report that dynamic control of surface temperature in rats, designed to mimic conductive cooling used clinically is the most effective means to regulate Tb after CHA.
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Laboratories (Gilroy, CA) (experiment B) or from a University of Alaska Fairbanks colony derived from Simonson Laboratories (experiment A and C). All animals were housed in pairs at 21.5-23.0°C on a 12L:12D photoperiod. A summary of experiments and number of animals used can be seen (Table 1) Experiment A: Dietary restriction & ad libitum, 0.5 mg/kg CHA, IP Prior research had shown that DR increases sensitivity to the Tb lowering effects of 0.5 mg/kg CHA, but V O2 was not measured as an indication of thermogenesis. Here we asked if CHA suppresses V O2 prior to the decrease in Tb, consistent with suppression of thermogenesis, and test the influence of 36 days of every-other-day feeding on the thermolytic response to CHA.
Temperature data loggers (iButton; Maxim Integrated, Sunnyvale, CA) were coated with wax and surgically implanted into the abdominal cavity and programmed to record temperature every 10 minutes. After a 10-14 day post-operative recovery period rats were either fed every other day (DR) or AL up to 40 days. Feeding or food removal was done at 10-11AM every day. Body weights were measured every four days. Between 36-40 days after starting the DR protocol animals were moved to a clean cage and housed individually at an ambient temperature of 16.2 ± 0.5°C (mean ± SD) for 24h prior to treatment. Rats were moved to a metabolic chamber for 3 JPET #241315 temperature of 17.0±0.5°C (mean ± SD) 24h before injections and remained at this ambient temperature until 24h after injection. Each of the 5 pairs of animals received a different treatment per week based on a balanced cross-over design (Supplemental Table 1 ). All treatments were given via IP injections and consisted of CHA (1.0 mg/kg), CHA Vehicle (1.0 mL/kg), capadenoson (1.0 and 2.0 mg/kg), and capadenoson vehicle (1.0 mL/kg). Heart rate was monitored with a digital stethoscope (Littmann © Model 4000 electronic stethoscope (3M, St.
Paul, MN). was also cannulated using C30PU-RJV1420 catheters; both cannula were passed through an inter-scapular incision where they were attached to a 2 channel vascular harness (VAD115AB; Instech). For post-operative recovery animals were housed individually with cotton pads substituted for wood shavings. Sutures were removed 7-10 days post op and catheter maintenance was done by flushing every 5 days using saline followed by filling with a locking solution of heparin/glycerol (500 IU/mL, 50:50) to prevent clotting. On the day of the experiment, animals were placed on the cage surface with the initial surface temperature set to 17°C. CHA was administered by continuous IV infusion (0.25 mg/kg/h). When animals approached a target Tb of 32°C, surface temperature was increased to 32°C to maintain target temperature.
CHA (CAS 36396-99-3) is eliminated with a half-life of approximately 2 hours when given subcutaneously (Tuovinen and Tarhanen, 2004) and is a full A1AR agonist (van der Wenden et al., 1995 Solutions for injection were sterilized by 0.2µm filtration (Acrodisc syringe filter; Pall corp., Port Washington, NY).
Oxygen consumption (V O2)
V O2 was measured using open-flow respirometry in conjunction with LabGraph respirometry acquisition and analysis software according to (Toien, 2013) and (Jinka et al., 2011) . The accuracy and integrity of the system was calibrated by burning ethanol (100%) following established methodology (Toien, 2013) ; analyzers were manually calibrated with atmospheric reference air (~0.03% CO2), zero air (~0% CO2), and span gas (~0.51% CO2) before each group of experiments and auto-calibrated subsequently every two hours. V O2 data was synchronized with Tb by subtracting a lag time of 4 min calculated as the volume of the chamber and length of the outlet tube.
Statistical Analysis
Variation in Tb , body mass, and V O2 was analyzed using repeated measures linear mixed-effect models (Domidenko, 2004) to account for within-rat correlations and to model time trajectories Post-hoc t-tests showed that the CHA group was significantly different than vehicle in DR animals (p<0.05) at 40-120 min after injection. The Tb in the AL group after CHA was not different from vehicle (p>0.05). We observed a bimodal distribution in the 4 AL fed rats after giving 0.5mg/kg CHA ; two rats maintained Tb similar to vehicle while the other two showed a decrease in Tb similar to DR rats given CHA [Supplemental Figure 1 ].
In order to see if CHA decreased Tb as a result of an inhibition of thermogenesis, we measured V O2 as an indirect measure of both shivering and non-shivering thermogenesis in both DR an AL rats. Compared to rats given vehicle, V O2 tended to decrease in both AL and DR rats within 10 min after CHA injection ( Figure 3A ). V O2 stabilized at minimal levels within 30 to 50 min after CHA administration and tended to be lowest in the DR group. Pair-wise comparisons revealed significant differences between CHA treated and Vehicle treated DR rats at 40-120 minutes (p<0.05) and also between AL CHA and vehicle treated rats between 70-120 minutes (p<0.05).
IP injections with CHA or vehicle tended to produce an immediate increase in V O2 except where rats decreased Tb after CHA ( Figure 3B and Supplemental Figure 2 ). In these animals V O2
decreased before Tb and is consistent with a decrease in thermogenesis. Figure 6 ). Heart rate declined rapidly at the start of CHA infusion and bradycardia persisted throughout the infusion ( Figure 6 ).
Discussion
Thermolytics include antipyretic drugs such as acetaminophen and certain non-steroidal antiinflammatory drugs (Sullivan, 2011) . Here, we extend the definition of thermolytic to include drugs that suppress thermogenesis and decrease core Tb. Despite the ability of CHA to suppress thermogenesis precise control of Tb around a predetermined target temperature had yet to be demonstrated prior to this work. Our objectives were to define how dose of CHA and environmental temperature influence Tb in rats treated with CHA. IP Bolus injections using CHA at 0.5 and 1.0 mg/kg failed to produce consistent decreases in Tb, however, use of the higher dose decreased Tb in all animals down to or below our target temperature of 32°C at an ambient temperature of 17°C. From this, we hypothesized that overcooling could be prevented with cage surface temperature modulation and thus facilitate management of target Tb. Here, we report precise control of Tb using CHA coupled with dynamic control of cage surface temperature and show that modulation of dose alone is not sufficient to precisely manage target
Tb.
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Our results demonstrate robust thermolytic efficacy of CHA in rats and is a refinement of prior attempts with high doses of purine derivatives. AMP was the first purine reported to induce a torpor-like state in rats (Zhang et al., 2006) and both AMP and ATP were later tested in rats to lower Tb for therapeutic benefit (Zhang et al., 2009; Zhang et al., 2013) . High doses were necessary in order to promote sufficient cooling, ultimately producing unwanted effects which discouraged further development. AMP induced a hypothermic response in mice (Swoap et al., 2007) and was later found to act as an A1AR agonist; (Muzzi et al., 2013 ) AMP-induced cooling was blocked using an A1AR antagonist in the CNS (Iliff and Swoap, 2012) . Targeting 
Although we found here that surface temperature modulation prevented overcooling, our data does not explain the large individual variation in Tb response to CHA. This variation was unexpected since prior work suggested more consistent responses between animals (Jinka et al., 2010), (Jinka et al., 2015) . We did not observe significant variation using the same animals with the partial agonist capadenoson, but consistency came at the cost of thermolytic efficacy.
Current knowledge suggests A1AR agonist-induced cooling is due to an inhibition of thermogenesis at a central site of action (Anderson et al., 1994; Tupone et al., 2013) . However, peripheral mechanisms such as the inhibition of lipolysis could also impair nonshivering thermogenesis in brown adipose tissue (Asakura, 2004; Viswanadha and Londos, 2006) . It is unclear whether these mechanisms are responsible for individual differences in Tb lowering effects of CHA, but our results reflect what might be expected in a diverse clinical population.
Similar variation in response to CHA is seen in ground squirrels where sensitivity to CHA depends on the hibernation season. In Arctic Ground Squirrels (AGS), stimulation of CNS A1ARs with CHA induces a torpor-like state, but the drug is effective only in the hibernation season (Jinka et al., 2011) . Seasonal sensitivity to CHA in AGS precedes a decrease in food intake and is predicted by a gradual decrease in Tb as animals approach the hibernation season (Olson et al., 2013) (Sheriff et al., 2012) . In rats, prolonged every-other-day feeding increases sensitivity to the temperature lowering effects of CHA as well as surface expression of A1AR in hypothalamus (Jinka et al., 2010) . While increases in surface expression of A1AR may contribute to increased sensitivity, prolonged restriction of diet is not a viable approach to normalize response to A1AR agonists in emergency medicine.
Shivering is one of the most problematic issues in TTM which can impede induction of hypothermia by doubling metabolic rate (Badjatia et al., 2008) , which leads to a stress-like response . Despite the importance of metabolism reduction, one of the primary desired effects in administering TTM, limited O2 consumption data has been reported for other thermolytics in 
development. Recently however, it was revealed that O2 consumption was reduced using TRPv3 agonists to induce hypothermia in mice, but these results could not be replicated in rats (Feketa and Marrelli, 2015) . Here, evidence supporting inhibition of thermogenesis comes from a decrease in the rate of oxygen consumption (V O2) that precedes a decrease in Tb. A similar hysteresis of V O2 and Tb decline is seen during the onset of hibernation and torpor (Jinka et al., 2011) .
Generalization of the current results in rats to other non-hibernating species such as swine and humans is likely because rats do not hibernate naturally. By contrast, many strains of laboratory mice spontaneously enter shallow torpor in response to fasting (Geiser, 2004) . Results from studies using mice may not translate to species that do not hibernate, as evident in the study of TRPv3 agonists (Feketa and Marrelli, 2015) . For this reason mice are less preferred in the investigation of thermolytic efficacy in comparison to rats or swine.
One limitation of this study, and others using small animals to study whole-body cooling is that surface area to weight ratio is far smaller than in larger animals including humans. An important next step in evaluating thermolytic efficacy is to utilize larger animals. In the present study the rate of cooling was faster following IP injection than with continuous IV administration because a loading dose was not given prior to IV infusion. Another limitation not addressed here is the 
A recent trial (Nielsen et al., 2013) showed no difference in outcome in patients cooled to 33°C
vs. 36°C and questioned the utility of cooling to 33°C. By contrast, an exhaustive number (over 50) of preclinical studies demonstrate that deeper cooling is better (Lyden et al., 2006; Polderman, 2009) . Moreover, Nielsen noted shivering at 33°C and 36°C and no differences were found in other adverse effects of 33°C vs. 36°C; other studies confirm shivering at 36°C (Callaway et al., 2015b) . Importantly, the benefit to risk of colder Tb may increase as severity of brain injury increases (Yenari and Han, 2012) . In response to the Nielsen paper the original In summary, we show pronounced thermolytic efficacy of CHA with unexplained variation that is resolved under dietary restriction, but is not resolved with dose in ad libitum fed animals.
Although high thermolytic efficacy produced over-cooling in some animals, dynamic control of surface temperature allowed for fine tuning and maintenance of a prescribed target Tb. This approach to reduce and maintain target Tb in rodents is a refinement over fixed ambient temperatures or evaporative cooling protocols where animals are sprayed with water or alcohol to facilitate heat loss (Klahr et al., 2016) , and mimics surface cooling used in the clinic. This new Arrowheads indicate time when rats were picked up for heart rate measurements. 
